Literature DB >> 15760148

Synthesis of a potent and selective inhibitor of p90 Rsk.

David J Maloney1, Sidney M Hecht.   

Abstract

[reaction: see text] The synthesis of the naturally occurring kaempferol glycoside SL0101 has been accomplished, as has its biochemical evaluation. SL0101 exhibits selective and potent p90 Rsk inhibitory activity at nanomolar concentrations without inhibiting the function of upstream kinases such as MEK, Raf, or PKC. The synthesis verified the structural assignment of the natural product and has provided access to material sufficient for detailed biological evaluation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15760148     DOI： 10.1021/ol0500463

Source DB:  PubMed          Journal:  Org Lett        ISSN： 1523-7052            Impact factor:   6.005


  23 in total

1.  Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.

Authors:  Jinliang Li; Michael D Kritzer; Jennifer J Carlisle Michel; Andrew Le; Hrishikesh Thakur; Marjorie Gayanilo; Catherine L Passariello; Alejandra Negro; Joshua B Danial; Behzad Oskouei; Michael Sanders; Joshua M Hare; Andre Hanauer; Kimberly Dodge-Kafka; Michael S Kapiloff
Journal:  Circ Res       Date:  2012-09-20       Impact factor: 17.367

2.  Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor.

Authors:  Darkhan Utepbergenov; Urszula Derewenda; Natalya Olekhnovich; Gabriela Szukalska; Budhaditya Banerjee; Michael K Hilinski; Deborah A Lannigan; P Todd Stukenberg; Zygmunt S Derewenda
Journal:  Biochemistry       Date:  2012-08-06       Impact factor: 3.162

Review 3.  The unusual mechanism of inhibition of the p90 ribosomal S6 kinase (RSK) by flavonol rhamnosides.

Authors:  Darkhan Utepbergenov; Zygmunt S Derewenda
Journal:  Biochim Biophys Acta       Date:  2013-03-27

4.  Regioselective Synthesis of a C-4'' Carbamate,C-6'' n-Pr Substituted Cyclitol Analogue of SL0101.

Authors:  Yu Li; Zachary M Sandusky; Rajender Vemula; Qi Zhang; Bulan Wu; Shinji Fukuda; Mingzong Li; Deborah A Lannigan; George A O'Doherty
Journal:  Org Lett       Date:  2020-02-03       Impact factor: 6.005

5.  De novo asymmetric syntheses of SL0101 and its analogues via a palladium-catalyzed glycosylation.

Authors:  Mingde Shan; George A O'Doherty
Journal:  Org Lett       Date:  2006-10-26       Impact factor: 6.005

6.  Facile oxidative cleavage of 4-O-benzyl ethers with dichlorodicyanoquinone in rhamno- and mannopyranosides.

Authors:  David Crich; Olga Vinogradova
Journal:  J Org Chem       Date:  2007-03-22       Impact factor: 4.354

7.  Synthesis and Biological Evaluation of 4'-Substituted Kaempfer-3-ols.

Authors:  Sugyeom Kim; Yu Li; Lin Lin; Peyton R Sayasith; Ariel T Tarr; Eric B Wright; Sharia Yasmin; Deborah A Lannigan; George A O'Doherty
Journal:  J Org Chem       Date:  2020-02-27       Impact factor: 4.354

8.  Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability.

Authors:  Michael K Hilinski; Roman M Mrozowski; David E Clark; Deborah A Lannigan
Journal:  Bioorg Med Chem Lett       Date:  2012-03-13       Impact factor: 2.823

9.  Identification of quercitrin as an inhibitor of the p90 S6 ribosomal kinase (RSK): structure of its complex with the N-terminal domain of RSK2 at 1.8 Å resolution.

Authors:  Urszula Derewenda; Mykhaylo Artamonov; Gabriela Szukalska; Darkhan Utepbergenov; Natalya Olekhnovich; Hardik I Parikh; Glen E Kellogg; Avril V Somlyo; Zygmunt S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-01-19

10.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.